Sanofi performed "very consistently" in emerging markets in the second quarter, with steady growth across geographies, according to Olivier Charmeil, the French group’s executive vice president, General Medicines & Emerging Markets, although the economic turmoil in Venezuela is expected to drag on performance this year.
Group emerging market sales were "broadly stable" versus last year, rising by 7% excluding Venezuela, CEO Olivier Brandicourt said during...